Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout
Journey Medical Corporation to Participate in October 2025 Investor Conferences
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing
H.C. Wainwright 27th Annual Global Investment Conference
Stay informed and receive company updates straight to your inbox.